How are antiviral agents administered to patients in the treatment of HBV-related polyarteritis nodosa (PAN)?

Updated: Dec 17, 2020
  • Author: Dana Jacobs-Kosmin, MD, FACP; Chief Editor: Herbert S Diamond, MD  more...
  • Print

Antiviral agents are begun after steroid withdrawal to enhance immunologic clearance of HBV-infected hepatocytes and favor seroconversion. Agents studied included vidarabine, [71] which was replaced by interferon-α2b, [72] and later by lamivudine. [70] It is recommended that lamivudine be continued for 6 months or stopped at the time of seroconversion to hepatitis B surface antibody. (These recommendations may change; combination treatment and prolonged courses of antivirals are currently being investigated in the management of HBV).

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!